CagriSema: How the Amylin/GLP-1 Combo Affects Your Gut

Weight loss medications have been getting progressively more powerful — and progressively more complex in how they interact with the gut. CagriSema, Novo Nordisk's combination of cagrilintide (a long-acting amylin analogue) and semaglutide (the active ingredient in Ozempic and Wegovy), represents the next step in this progression. Phase 3 REDEFINE trial data showed average weight loss of approximately 22-25% — surpassing anything available outside of surgical intervention. But for people with SIBO, IBS, or underlying motility problems, more powerful gut-active drugs raise proportionally more serious concerns. Amylin is a hormone that works in the brain and gut simultaneously, and adding it to semaglutide's already-significant motility effects creates a combination that deserves careful consideration. This article explains the science, the trial data, and what it means for your gut health.

What Is Amylin and What Does It Do to Your Gut?

Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It was discovered in the 1980s and found to play a critical role in postprandial glucose regulation — but its effects extend far beyond blood sugar. Amylin acts centrally in the brainstem to reduce food intake and slow gastric emptying. It also works peripherally in the gut to delay nutrient absorption and suppress glucagon secretion. The FDA approved the synthetic amylin analogue pramlintide (Symlin) for diabetes in 2005, but its short half-life and requirement for thrice-daily injection limited its use.

Cagrilintide is a next-generation amylin analogue engineered for once-weekly dosing. It has approximately 10-fold higher potency than pramlintide at the amylin receptor and a dramatically extended half-life achieved through acylation (the same chemical strategy used to extend semaglutide's duration of action). The amylin receptor relevant to gut function is the AMY1 receptor, a complex of the calcitonin receptor and receptor activity-modifying protein 1 (RAMP1). This receptor is expressed in both the dorsal vagal complex of the brainstem and in enteric neurons throughout the gut wall. Amylin's gastric emptying delay works through both central vagal pathways and direct enteric nervous system effects.

The REDEFINE Trials: Efficacy and GI Tolerability Data

The REDEFINE phase 3 program evaluated CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, both weekly) versus placebo and versus semaglutide alone across multiple obesity populations. REDEFINE 1 enrolled adults with obesity without type 2 diabetes, and the results were striking: CagriSema produced 22.7% mean weight reduction at 68 weeks compared to 10.8% with semaglutide alone and 2.3% with placebo. This places CagriSema performance closer to surgical outcomes than any previously approved medication.

The GI adverse event profile, however, tells an important story for motility-sensitive patients. In REDEFINE 1, nausea occurred in approximately 48% of CagriSema-treated patients versus 38% with semaglutide alone. Vomiting affected 22% of CagriSema patients versus 14% with semaglutide. Constipation was reported in 21% of CagriSema patients versus 18% with semaglutide. Discontinuation due to GI adverse events was approximately 5% in the CagriSema arm. While the absolute rates are numerically higher than semaglutide alone, the difference is meaningful: adding cagrilintide to semaglutide significantly increases the GI burden, particularly nausea and vomiting — both markers of upper GI motility disruption.

Critically, the gastric emptying delay with CagriSema appears to be additive rather than synergistic. Phase 1 pharmacodynamic studies showed that cagrilintide alone delayed gastric emptying by approximately 20-25% compared to placebo, while semaglutide alone delayed it by approximately 30-35%. The combination produced delays of approximately 45-55% — suggesting additive effects from two mechanistically distinct pathways. This is a substantial perturbation of upper GI physiology with implications that extend well beyond gastric emptying itself.

What Additive Motility Suppression Means for SIBO Risk

For SIBO patients and those prone to bacterial overgrowth, the additive gastric emptying delay of CagriSema is the critical concern. The migrating motor complex (MMC) — the rhythmic small intestinal contractions that sweep bacteria downstream between meals — is impaired by GLP-1 receptor activation. Amylin receptor activation adds another layer of suppression via vagal pathways that independently regulate MMC activity. A drug combination that delays gastric emptying by 45-55% is doing so through two separate mechanisms, which means neither mechanism alone is responsible and addressing just one would not fully restore motility.

The practical consequence is that SIBO risk with CagriSema is likely higher than with semaglutide alone, and possibly substantially higher. There are currently no published studies measuring small intestinal bacterial populations or breath test results in CagriSema-treated patients, so this remains an inference from mechanistic and pharmacodynamic data rather than direct clinical measurement. But the pattern — two motility-suppressing mechanisms, additive gastric emptying delay, higher nausea and vomiting rates — is consistent with a drug that meaningfully impairs the gut's bacterial housekeeping function.

CagriSema vs Semaglutide Alone: The Gut Health Tradeoff

The weight loss difference between CagriSema and semaglutide alone is substantial — approximately 22% versus 11% body weight reduction. For patients with severe obesity and metabolic complications, this difference may be clinically decisive. But from a gut health perspective, CagriSema represents a meaningfully greater intervention. It is worth thinking about this as a spectrum rather than a binary choice. Semaglutide alone already carries significant gut motility implications for SIBO-prone patients. CagriSema doubles down on those implications by adding a second mechanistically independent motility suppressant.

The 'convenience vs gut health tradeoff' with CagriSema is more pronounced than with any previous single-agent GLP-1. The drug's extraordinary efficacy for weight loss is real and clinically meaningful. But so is the gut burden. For a patient with a clean gut history and no predisposition to SIBO, this tradeoff may be acceptable given the obesity-related health risks. For a patient who has already struggled with recurrent SIBO, who has underlying structural motility issues, or who has undergone abdominal surgery, CagriSema's motility profile warrants serious caution.

Practical Guidance for Gut-Sensitive Patients

CagriSema was not yet FDA-approved as of mid-2026, with Novo Nordisk having submitted the regulatory dossier based on REDEFINE trial data. When it does reach the market, gut-sensitive patients will face real decisions. Here are practical considerations to discuss with your care team.

First, know your baseline. A lactulose breath test before starting any GLP-1-containing medication gives you objective data about whether active SIBO is already present. If your baseline test is positive, treating SIBO before initiating CagriSema (or any GLP-1) is strongly advisable. Second, if you are already on semaglutide and tolerating it well without SIBO recurrence, your baseline motility is likely adequate to handle GLP-1 agonism. But adding cagrilintide on top of established semaglutide introduces a new motility perturbation — it would be prudent to recheck a breath test 3-6 months after transitioning to CagriSema. Third, prokinetic support (low-dose erythromycin, prucalopride, or tegaserod where available) may help offset combined motility suppression, though no clinical trials have specifically evaluated prokinetics as preventive therapy alongside CagriSema.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.